These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27265466)

  • 1. Characterization of two anti-dengue human monoclonal antibodies prepared from PBMCs of patients with dengue illness in Thailand.
    Li ZY; Yamashita A; Kawashita N; Sasaki T; Pan Y; Ono KI; Ikuta K; Li YG
    Acta Virol; 2016 Jun; 60(2):166-73. PubMed ID: 27265466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.
    Sasaki T; Setthapramote C; Kurosu T; Nishimura M; Asai A; Omokoko MD; Pipattanaboon C; Pitaksajjakul P; Limkittikul K; Subchareon A; Chaichana P; Okabayashi T; Hirai I; Leaungwutiwong P; Misaki R; Fujiyama K; Ono K; Okuno Y; Ramasoota P; Ikuta K
    Antiviral Res; 2013 Jun; 98(3):423-31. PubMed ID: 23545366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection.
    Setthapramote C; Sasaki T; Puiprom O; Limkittikul K; Pitaksajjakul P; Pipattanaboon C; Sasayama M; Leuangwutiwong P; Phumratanaprapin W; Chamnachanan S; Kusolsuk T; Jittmittraphap A; Asai A; Arias JF; Hirai I; Kuhara M; Okuno Y; Kurosu T; Ramasoota P; Ikuta K
    Biochem Biophys Res Commun; 2012 Jul; 423(4):867-72. PubMed ID: 22713454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine.
    Tsai WY; Chen HL; Tsai JJ; Dejnirattisai W; Jumnainsong A; Mongkolsapaya J; Screaton G; Crowe JE; Wang WK
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30185598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of Monoclonal Antibodies against Dengue Virus Type 4 and Identification of Enhancing Epitopes on Envelope Protein.
    Tang CT; Liao MY; Chiu CY; Shen WF; Chiu CY; Cheng PC; Chang GJ; Wu HC
    PLoS One; 2015; 10(8):e0136328. PubMed ID: 26309127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.
    Tsai WY; Lai CY; Wu YC; Lin HE; Edwards C; Jumnainsong A; Kliks S; Halstead S; Mongkolsapaya J; Screaton GR; Wang WK
    J Virol; 2013 Dec; 87(23):12562-75. PubMed ID: 24027331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.
    Smith SA; de Alwis AR; Kose N; Jadi RS; de Silva AM; Crowe JE
    J Virol; 2014 Nov; 88(21):12233-41. PubMed ID: 25100837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
    de Alwis R; Smith SA; Olivarez NP; Messer WB; Huynh JP; Wahala WM; White LJ; Diamond MS; Baric RS; Crowe JE; de Silva AM
    Proc Natl Acad Sci U S A; 2012 May; 109(19):7439-44. PubMed ID: 22499787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.
    Smith SA; de Alwis AR; Kose N; Harris E; Ibarra KD; Kahle KM; Pfaff JM; Xiang X; Doranz BJ; de Silva AM; Austin SK; Sukupolvi-Petty S; Diamond MS; Crowe JE
    mBio; 2013 Nov; 4(6):e00873-13. PubMed ID: 24255124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of Individuals from a Dengue-Endemic Region Helps Define the Footprint and Repertoire of Antibodies Targeting Dengue Virus 3 Type-Specific Epitopes.
    Andrade DV; Katzelnick LC; Widman DG; Balmaseda A; de Silva AM; Baric RS; Harris E
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design.
    Li XQ; Qiu LW; Chen Y; Wen K; Cai JP; Chen J; Pan YX; Li J; Hu DM; Huang YF; Liu LD; Ding XX; Guo YH; Che XY
    J Gen Virol; 2013 Oct; 94(Pt 10):2191-2201. PubMed ID: 23851440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes.
    Gallichotte EN; Baric TJ; Yount BL; Widman DG; Durbin A; Whitehead S; Baric RS; de Silva AM
    PLoS Pathog; 2018 Feb; 14(2):e1006934. PubMed ID: 29481552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1.
    Messer WB; Yount BL; Royal SR; de Alwis R; Widman DG; Smith SA; Crowe JE; Pfaff JM; Kahle KM; Doranz BJ; Ibarra KD; Harris E; de Silva AM; Baric RS
    J Virol; 2016 May; 90(10):5090-5097. PubMed ID: 26962223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.
    Costin JM; Zaitseva E; Kahle KM; Nicholson CO; Rowe DK; Graham AS; Bazzone LE; Hogancamp G; Figueroa Sierra M; Fong RH; Yang ST; Lin L; Robinson JE; Doranz BJ; Chernomordik LV; Michael SF; Schieffelin JS; Isern S
    J Virol; 2013 Jan; 87(1):52-66. PubMed ID: 23077306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
    Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
    J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dengue virus antibody database: Systematically linking serotype-specificity with epitope mapping in dengue virus.
    Chaudhury S; Gromowski GD; Ripoll DR; Khavrutskii IV; Desai V; Wallqvist A
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005395. PubMed ID: 28222130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotypic Differences in Dengue Virus Neutralization Are Explained by a Single Amino Acid Mutation That Modulates Virus Breathing.
    Dowd KA; DeMaso CR; Pierson TC
    mBio; 2015 Nov; 6(6):e01559-15. PubMed ID: 26530385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody.
    Luo YY; Feng JJ; Zhou JM; Yu ZZ; Fang DY; Yan HJ; Zeng GC; Jiang LF
    BMC Microbiol; 2013 Aug; 13():194. PubMed ID: 23987307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.